Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts at ESMO 2024 Annual Meeting.

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts at ESMO 2024 Annual Meeting.

BARCELONA, Spain, September 20, 2024 /PRNewswire/ — Highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress took place from September 13 to 17 to Barcelona, ​​Spain. As one …

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts at ESMO 2024 Annual Meeting. Read More
The hottest AI applications are driving up the latest investment cycles. Suddenly, it feels very much like 2021 in Silicon Valley for a select few.